Protalix BioTherapeutics (PLX) Liabilities and Shareholders Equity (2010 - 2026)

Protalix BioTherapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $102.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 38.49% year-over-year to $102.3 million; the TTM figure through Mar 2026 stood at $345.4 million (up 14.99% YoY), while the FY2025 annual figure was $82.3 million, up 12.16% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $102.3 million, up from $82.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $102.3 million in Q1 2026, with the low at $55.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $78.5 million (2025), against an average of $76.7 million.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity plunged 43.96% in 2022, then surged 54.42% in 2023.
• Protalix BioTherapeutics' Liabilities and Shareholders Equity stood at $55.8 million in 2022, then surged by 51.35% to $84.4 million in 2023, then declined by 13.05% to $73.4 million in 2024, then grew by 12.16% to $82.3 million in 2025, then climbed by 24.28% to $102.3 million in 2026.
• Business Quant data shows PLX's Liabilities and Shareholders Equity at $102.3 million in Q1 2026, $82.3 million in Q4 2025, and $82.3 million in Q3 2025.